Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Shawna Purcell

Internal Medicine Olympia, WA Medical Doctor

NPI 1861683799 CMS profile 311093

404 Yauger Way Sw Ste 100, Olympia, WA 98502

Open in the dashboard

General payments

$293,998

560 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shawna Purcell of Olympia, WA is reported in the CMS Open Payments database as having received $293,998 across 560 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $58,360 96
2024 General $32,081 58
2023 General $27,997 59
2022 General $72,898 123
2021 General $37,553 85
2020 General $15,669 40
2019 General $49,441 99

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shawna Purcell
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Shawna Purcell were reported at $58,360. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Shawna Purcell Internal Medicine median Middle half National median
2019 $49,441 $159 $48–$570 $163
2020 $15,669 $119 $33–$402 $114
2021 $37,553 $135 $37–$521 $132
2022 $72,898 $141 $42–$496 $149
2023 $27,997 $149 $45–$519 $160
2024 $32,081 $154 $47–$537 $164
2025 $58,360 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lilly USA, LLC $293,484 535 payments
  2. AstraZeneca Pharmaceuticals LP $212 6 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $121 8 payments
  4. Abbott Laboratories $62 4 payments
  5. Novo Nordisk Inc $56 4 payments
  6. Medtronic, Inc. $35 1 payment
  7. Biohaven Pharmaceuticals, Inc. $15 1 payment
  8. Medtronic MiniMed, Inc. $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $251,175 380 payments
  2. Travel and Lodging $33,485 76 payments
  3. Consulting Fee $5,950 3 payments
  4. Food and Beverage $3,368 99 payments
  5. Education $21 2 payments
Products named General payments · program years 2019–2025
  1. TRULICITY $111,308 225 payments
  2. MOUNJARO $106,538 184 payments
  3. ZEPBOUND $1,362 3 payments
  4. FARXIGA $201 5 payments
  5. JARDIANCE $121 8 payments
  6. BYDUREON $75 2 payments
  7. BASAGLAR $62 4 payments
  8. Ozempic $56 4 payments
  9. RYBELSUS $43 3 payments
  10. InPen $35 1 payment
  11. Other $105 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

445

Median for Internal Medicine: 777

Drug cost

$257,732

Median for Internal Medicine: $73,373

Branded share of claims

80.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 126 $131,158
Jardiance Empagliflozin Brand 93 $66,042
Ozempic Semaglutide Brand 17 $23,612
Synjardy Xr Empagliflozin/Metformin Hcl Brand 35 $19,462
Trulicity Dulaglutide Brand 12 $11,882
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 11 $1,396
Np Thyroid Thyroid,pork Brand 26 $1,037
Testosterone Cypionate Generic 20 $831
Bupropion Hcl Sr Bupropion Hcl Brand 22 $809
Cyanocobalamin Injection Cyanocobalamin (Vitamin B-12) Brand 17 $476

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $26,119
$26,119 126 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

560 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record